Literature DB >> 10590413

Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition.

M A Badalamente1, A Stracher.   

Abstract

Inhibition of muscle degeneration by the tripeptide calpain inhibitor, leupeptin, was tested in vivo in a dystrophin-deficient mdx murine model. In a short-term control study, intramuscular administration of leupeptin for 30 days inhibited muscle degeneration as assessed by histologic analysis. Calpain inhibition could be correlated with retention of myofiber size and our results suggest that this may be a promising treatment modality in human Duchenne muscular dystrophy. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590413     DOI: 10.1002/(sici)1097-4598(200001)23:1<106::aid-mus14>3.0.co;2-d

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  30 in total

Review 1.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

Review 2.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

Review 3.  Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: role of ionic changes.

Authors:  D G Allen; N P Whitehead; E W Yeung
Journal:  J Physiol       Date:  2005-07-07       Impact factor: 5.182

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

5.  Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.

Authors:  Kristine M Wadosky; Luge Li; Jessica E Rodríguez; Jin-Na Min; Dan Bogan; Jason Gonzalez; Cam Patterson; Joe N Kornegay; Monte Willis
Journal:  Muscle Nerve       Date:  2011-08-08       Impact factor: 3.217

6.  Enhanced Ca²⁺ influx from STIM1-Orai1 induces muscle pathology in mouse models of muscular dystrophy.

Authors:  Sanjeewa A Goonasekera; Jennifer Davis; Jennifer Q Kwong; Federica Accornero; Lan Wei-LaPierre; Michelle A Sargent; Robert T Dirksen; Jeffery D Molkentin
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 7.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 8.  Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy.

Authors:  Chad D Markert; Anthony Atala; Jennifer K Cann; George Christ; Mark Furth; Fabrisia Ambrosio; Martin K Childers
Journal:  PM R       Date:  2009-06       Impact factor: 2.298

9.  Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy.

Authors:  Paul Dowling; Philip Doran; Kay Ohlendieck
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 10.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.